BY MIRABEL ODETA
The U.S. Food and Drug Administration has approved a new weight-loss pill developed by Eli Lilly, marking a significant moment in the rapidly expanding market for obesity treatments. The approval sets the stage for a fresh rivalry with Danish drugmaker Novo Nordisk, as both companies compete to meet soaring demand for effective GLP-1-based medications among millions of Americans.
The newly approved drug, known as orforglipron and to be marketed under the brand name Foundayo, offers a convenient once-daily oral alternative to injectable treatments. Designed to target the GLP-1 hormone, which regulates appetite and blood sugar, the pill has demonstrated promising results in clinical trials. Patients who took the medication experienced weight loss ranging from 12% to 15% of their total body weight, placing it among the more effective options currently available.
Eli Lilly announced that Foundayo will be available starting April 6 through its LillyDirect platform, with a monthly price of $149 for the lowest dose for customers paying out of pocket. The company plans to expand distribution shortly afterward to include retail pharmacies and telehealth providers, aiming to make the drug widely accessible across the United States.
According to Eli Lilly CEO David Ricks, the pill is intended not only for individuals seeking to lose weight but also for those aiming to maintain long-term weight reduction. He also noted that the company has submitted the drug for approval in more than 40 countries, with expectations that several major markets could grant authorization within the year. Regions such as the Gulf states may move particularly quickly in reviewing the treatment.
The FDA’s decision was accelerated under a new voucher initiative designed to speed up the review of drugs considered important for public health. Despite the faster timeline, officials emphasized that the evaluation process remained thorough and met all regulatory standards.
This approval places Eli Lilly in direct competition with Novo Nordisk, which has been a dominant force in the GLP-1 market. Novo initially led the space with injectable treatments such as Ozempic and Wegovy, but Eli Lilly has since gained significant ground in the U.S. market. Novo also introduced an oral version of Wegovy earlier this year, capturing early demand among patients seeking non-injectable options.
One of Foundayo’s key advantages lies in its flexibility. Unlike Novo’s oral Wegovy, which must be taken first thing in the morning on an empty stomach with strict timing before food or other medications, Foundayo can be taken at any time of day, with or without meals. This ease of use could play a major role in patient adoption, especially among those who prefer simpler medication routines.
Market analysts suggest that while injectable GLP-1 drugs are likely to remain the most effective option for significant weight loss, oral medications could carve out a meaningful share of the market. Estimates indicate that pills may account for around 20% of the obesity treatment market by 2030, particularly by attracting patients who are hesitant to use injections or are new to GLP-1 therapies.
Clinical trial data further supports the drug’s potential. In a 72-week late-stage study, participants lost approximately 12% of their body weight, with results stabilizing over time. Earlier mid-stage trials showed even higher reductions, approaching 15%. However, like other medications in its class, Foundayo is associated with side effects, most commonly mild to moderate gastrointestinal issues such as nausea and vomiting.
The drug also carries a boxed warning—the FDA’s most serious safety label—highlighting a potential risk of thyroid C-cell tumors. This warning is consistent with other GLP-1 treatments, including both oral and injectable versions of Wegovy.
The approval of Foundayo reflects a broader shift in the weight-loss treatment landscape, where convenience, accessibility, and affordability are becoming just as important as effectiveness. As more patients seek medical solutions for obesity, the competition between pharmaceutical giants like Eli Lilly and Novo Nordisk is expected to drive innovation, expand treatment options, and potentially bring costs down over time.
With demand for weight-loss therapies continuing to surge, the introduction of a daily pill could open the door for a wider population of patients to begin treatment, reshaping how obesity is managed in the years ahead.
Original article
Comments